Teramoto H, Castellone MD, Malek RL, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-Ras V12[J].Oncogene,2005,24:489-501.
[2]
Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small lung cancer: a combined analysis of 881 cases[J].Carcinogenesis,1999(20):1507-1510.
[3]
Domenico Coppola, Marianna szabo, David Boulware, et al. Correlation of Osteopontin protein expression and pathological stage across a wide variety of tumor histologies[J]. Clinical Cancer Research,2004,10:184-190.
Yohko UK, Jonathan Sleeman, Hideki Fujii, et al. CD44 Variants but not CD44s Cooperate with ?1-containing Integrins to Permit Cells to Bind to Osteopontin Independently of Arginine-glycine-aspartic Acid, thereby Stimulating Cell Motility and Chemotaxis[J]. Cancer Research, 1999,59: 219-226.
[6]
Teramoto H, Castellone MD, Malek R L, et al. Autocrine activation of an osteopontin- CD44-Rac pathway enhances invasion and transformation by H-RasV12[J].Oncogene,2005,24:489-501.
[7]
Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene[J]. Br J Cancer,2000, 83: 156-163.
[8]
Jin zhang, Kazuhisa Takahashi, Fumiyuki Takahashi, et al. Differential psteopontin expression in lung cancer[J].Cancer letters, 2001,171:215-222.
[9]
Chang Y S,Kim H J,Chang J,et al. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer[J].Lung Cancer,2007,57(3):373-380.
[10]
Hu Z, Lin D, Yuan J, et al. Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non-Small Cell Lung Cancer[J]. Clinical Cancer Research,2005, 11:4646-4652.
[11]
Boldrini L, Donati VD, Omodarme M, et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer[J]. Br J Cancer,2005,93:453-457.
[12]
Fasano M,Sabatini MT,Wieczorek R,et al.CD44 and its v6 spliced variant in lung tumors[J].Cancer,1997,80(1):34-41.
[13]
Tran TA, Kallakury BV, Sheehan CE,et al. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas[J]. Hum Pathol,1997,28(7):809-814.
[14]
Miyoshi T, Kondo K,Hino N, et al. The expression of the CD44 variant exon 6 is assocated with lymph node metastasis in non-small cell lung cancer[J]. Clinical Cancer Research,1997,3,1289-1297.
[15]
Hirata T, Fukuse T, Naiki H, et al. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor[J]. Cancer Research,1998(58):1108-1110.
[16]
Hofmann M, Rudy W, Gunthert U, et al. A link between ras and metastatic behavior of tumor cells; ras induces CD44 promoter activity and leads to low level expressions of metastasis-specific variants of CD44 in CREF cells[J].Cancer Res,1993,53:1516-1521.
[17]
Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells[J]. J Biol Cheml,2004,279:11051-11064.
